Wird geladen...
CBMT-37. FDA-APPROVED HDAC INHIBITORS ANTAGONIZE THE WARBURG EFFECT AND CAUSE UNIQUE METABOLIC VULNERABILITIES
Histone deacetylase inhibition is a potential new strategy for the treatment of glioblastoma (GBM) and FDA-approved for multiple myeloma. However, resistance to therapy is a major issue. By conducting a global transcriptome with subsequent gene set enrichment analysis in stem-like GBM cells and PDX...
Gespeichert in:
| Veröffentlicht in: | Neuro Oncol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217162/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.156 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|